Epizyme Inc. buy tamam
Start price
17.12.19
/
50%
€16.60
Target price
04.11.21
€24.80
Performance (%)
-45.78%
End price
08.11.20
€9.00
Summary
This prediction ended on 08.11.20 with a price of €9.00. The BUY prediction by tamam for Epizyme Inc. performed very badly with a performance of -45.78%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Epizyme Inc. | - | - | - | - |
| iShares Core DAX® | 2.594% | -1.158% | 14.782% | 16.813% |
| iShares Nasdaq 100 | 3.553% | -1.727% | 43.265% | 44.227% |
| iShares Nikkei 225® | 0.687% | -8.354% | 18.454% | 1.361% |
| iShares S&P 500 | 2.209% | -0.942% | 31.361% | 42.812% |
Comments by tamam for this prediction
In the thread Epizyme Inc. diskutieren
Buy mit Kursziel 24,8
The FDA's Oncologic Drugs Advisory Committee will meet on Wednesday, December 18, to review and discuss Epizyme's marketing application for tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.